|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||28.24 - 28.36|
|52-week range||15.20 - 28.79|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Here's why AstraZeneca agreed to pay Daiichi Sankyo another enormous sum to develop and commercialize an experimental cancer drug.
The British drugmaker has been bolstering its portfolio of cancer therapies, particularly ADCs, a major area of focus for the company as it also ploughs on with its coronavirus vaccine candidate. AstraZeneca said on Monday it would make staggered upfront payments totalling $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a promising class of therapies called antibody drug conjugates (ADC). The deal will not affect 2020 earnings forecast, AstraZeneca said.
Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan. The discussion follows a flurry of supply deals signed by the British drug maker for its experimental COVID-19 vaccine as it ramps up efforts for wider trials of the potential treatment. Daiichi Sankyo said in a statement on Friday that one of its subsidiaries would receive undiluted solution of the vaccine and then carry out formulation procedures, packaging, and storage in Japan.